L3VLUP
ProSign in

AZN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AZNJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AZN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterAZNJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 2021none listed holders, n.a.33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 2022none listed holders, n.a.33 holders, $26.9bn
Q3 2022none listed holders, n.a.36 holders, $25.4bn
Q4 2022none listed holders, n.a.35 holders, $27.6bn
Q1 2023none listed holders, n.a.42 holders, $24.5bn
Q2 2023none listed holders, n.a.38 holders, $25.0bn
Q3 2023none listed holders, n.a.37 holders, $18.9bn
Q4 2023none listed holders, n.a.31 holders, $19.0bn
Q1 2024none listed holders, n.a.32 holders, $19.7bn
Q2 2024none listed holders, n.a.35 holders, $20.4bn
Q3 2024none listed holders, n.a.28 holders, $22.3bn
Q4 2024none listed holders, n.a.37 holders, $20.4bn
Q1 2025none listed holders, n.a.32 holders, $20.5bn
Q2 2025none listed holders, n.a.31 holders, $18.4bn
Q3 2025none listed holders, n.a.32 holders, $23.7bn
Q4 2025none listed holders, n.a.29 holders, $27.8bn
Q1 202623 holders, $29.8bn34 holders, $35.6bn
Q2 202624 holders, $28.8bn33 holders, $39.1bn
AZN

Astrazeneca PLC

New listing

Holders
23
Reported value
$29.8bn
Buyers
33
Sellers
0

Not ranked this quarter: its new positions are allocations in a new listing.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AZN (6)

ExodusPoint Capital Management LP, Holocene Advisors LP, Jane Street Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Schonfeld Strategic Advisors LLC

Only JNJ (17)

AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, D. E. Shaw & Co., Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Markel Group Inc, MFS Investment Management, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Walleye Capital LLC, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →